Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuraxis, INCNRXS · Entity 6994 | Director · Chief Executive Officer | October 08, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuraxis, INC
Report date October 08, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,604 |
Reported balance
After 2026-10-08 transaction · row 1
1 source rowRow 1 · 2026-10-08 · Purchase · Acquired 268 · Balance 227,604 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 8, 2026 21:50 UTC | Neuraxis, INC NRXS · Entity 6994 | PurchaseCommon Stock | 268 | $4.84 | $1,297.12 |
DisclosureSEC source: 0001493152-26-046382 · ownership.xml · nonDerivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,604 Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:29 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionRSU · Derivative | 320,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 4 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:29 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 320,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 3 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · Not disclosed shares Expires not disclosed F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:29 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionStock Options · Derivative | 320,000 | $6.94 | $2,220,800.00 |
DisclosureSEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 2 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:29 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantCommon Stock | 199,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040274 · ownership.xml · nonDerivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,336 F1 · shares: Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. F1 · price: Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:25 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 193,329 | $6.28 | $1,214,106.12 |
DisclosureSEC source: 0001493152-26-038817 · ownership.xml · derivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,329 Underlying: Common Stock · 193,329 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 15:19 UTC | Neuraxis, INC NRXS · Entity 6994 | PurchaseCommon Stock | 8,060 | $1.96 | $15,797.60 |
DisclosureSEC source: 0001493152-26-015069 · ownership.xml · nonDerivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,178 Read SEC document |
| January 22, 2026 Filed Feb 27, 2026 02:23 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 94,173 | $4.63 | $436,020.99 |
DisclosureSEC source: 0001493152-26-008231 · ownership.xml · derivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,173 Underlying: Common Stock · 94,173 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Read SEC document |
| March 04, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 90,640 | $2.18 | $197,595.20 |
DisclosureSEC source: 0001641172-25-027017 · ownership.xml · derivative · entry 2 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,640 Underlying: Common Stock · 90,640 shares Expires not disclosed F2 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F2 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F2 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. Read SEC document |
| March 04, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 10,000 | $2.18 | $21,800.00 |
DisclosureSEC source: 0001641172-25-027017 · ownership.xml · derivative · entry 1 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. Read SEC document |
| January 03, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 70,019 | $2.42 | $169,445.98 |
DisclosureSEC source: 0001641172-25-027017 · ownership.xml · derivative · entry 3 Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,019 Underlying: Common Stock · 70,019 shares Expires not disclosed F3 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F3 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F3 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.